FCM
BNTX icon

Farallon Capital Management’s BioNTech BNTX Stock Holding History

Farallon Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,844
Closed -$406K – 178
2023
Q4 		$406K Hold
3,844
– – ﹤0.01% 112
2023
Q3 		$418K Hold
3,844
– – ﹤0.01% 120
2023
Q2 		$415K Sell
3,844
-133,800
-97% -$15M ﹤0.01% 131
2023
Q1 		$17.1M Sell
137,644
-2,356
-2% -$323K 0.09% 86
2022
Q4 		$21M Buy
+140,000
New +$21.5M 0.12% 81

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Farallon Capital Management's BNTX Position: Q1 2024 in Review

Farallon Capital Management sold out of BioNTech (BNTX) in Q1 2024, closing a stake of 3,844 shares — an estimated $406K sold.

Farallon Capital Management first reported a position in BNTX in Q4 2022 and held it in 5 quarters. The position peaked at $21M in Q4 2022. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2024.

  • Farallon Capital Management reported no remaining BioNTech position as of Q1 2024 after selling out during the quarter.
  • Farallon Capital Management sold 3,844 BioNTech shares in Q1 2024, an estimated $406K.
  • Farallon Capital Management first reported a position in BioNTech in Q4 2022 and held it in 5 quarters.
  • Farallon Capital Management's BioNTech position peaked at $21M in Q4 2022.
  • 287 funds tracked by Wall St. Rank held BioNTech as of Q1 2024.

Based on Farallon Capital Management's 13F filing for Q1 2024, filed 15 May 2024.